The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I study of birinapant (TL32711) combined with multiple chemotherapies evaluating tolerability and clinical activity for solid tumor patients.
Ravi K. Amaravadi
No relevant relationships to disclose
Neil N. Senzer
No relevant relationships to disclose
Lainie P. Martin
No relevant relationships to disclose
Russell J. Schilder
No relevant relationships to disclose
Patricia LoRusso
No relevant relationships to disclose
Kyriakos P. Papadopoulos
No relevant relationships to disclose
David Edward Weng
Employment or Leadership Position - Tetrologic Pharmaceuticals
Stock Ownership - Tetrologic Pharmaceuticals
Martin Graham
Employment or Leadership Position - Tetrologic Pharmaceuticals
Stock Ownership - Tetrologic Pharmaceuticals
Alex A. Adjei
No relevant relationships to disclose